Pyxis Oncology (NASDAQ:PYXS) Upgraded by Wall Street Zen to "Hold" Rating

Key Points

• Wall Street Zen upgraded Pyxis Oncology from a "sell" rating to a "hold" in its latest investor note.
• Pyxis reported Q results with a ($0.29) EPS that beat the ($0.35) consensus and revenue of $11.04 million versus expectations of $0.13 million.
• Analysts are mixed but moderately positive overall — five Buys, one Hold and one Sell — giving an average "Moderate Buy" rating and an average target price of $7.00.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Monday.

Several other research firms have also recently issued reports on PYXS. HC Wainwright reissued a "buy" rating and set a $7.00 price target on shares of Pyxis Oncology in a report on Tuesday, March 24th. Stifel Nicolaus cut their price target on shares of Pyxis Oncology from $9.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, March 24th. Royal Bank Of Canada dropped their target price on shares of Pyxis Oncology from $8.00 to $5.00 and set an "outperform" rating for the company in a report on Thursday, December 18th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $7.00.

Pyxis Oncology Price Performance

NASDAQ PYXS opened at $1.70 on Monday. The stock has a market capitalization of $106.81 million, a P/E ratio of -1.32 and a beta of 1.41. Pyxis Oncology has a 52-week low of $0.87 and a 52-week high of $5.55. The firm has a 50-day moving average price of $1.46 and a 200 day moving average price of $2.46.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.06. The firm had revenue of $11.04 million for the quarter, compared to analysts' expectations of $0.13 million. On average, equities research analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PYXS. Laurion Capital Management LP grew its position in shares of Pyxis Oncology by 32.3% in the fourth quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company's stock valued at $5,516,000 after purchasing an additional 1,170,505 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Pyxis Oncology by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company's stock valued at $4,804,000 after buying an additional 14,566 shares in the last quarter. 683 Capital Management LLC lifted its holdings in Pyxis Oncology by 69.9% in the 4th quarter. 683 Capital Management LLC now owns 891,910 shares of the company's stock worth $1,026,000 after buying an additional 366,910 shares in the last quarter. Jane Street Group LLC lifted its holdings in Pyxis Oncology by 158.8% in the 4th quarter. Jane Street Group LLC now owns 786,010 shares of the company's stock worth $904,000 after buying an additional 482,310 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Pyxis Oncology by 26.4% in the 4th quarter. Renaissance Technologies LLC now owns 728,380 shares of the company's stock worth $838,000 after buying an additional 152,044 shares in the last quarter. 39.07% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology NASDAQ: PYXS is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.